Laparoscopic Extravesical Submucosal Tunneling Ureteroneocystostomy Combined with Psoas Hitch for Medium-Length Distal Ureteral Defects in Adults.

OBJECTIVE: This study aims to describe the technique and feasibility of laparoscopic submucosal tunneling ureteroneocystostomy in combination with psoas hitch to restore urinary tract continuity in patients showing medium-length distal ureteral defects. MATERIALS AND METHODS: From January 2012 to April 2016, a total of 13 patients (4 males and 9 females) with a mean age of 37 years were performed with the laparoscopic operation of ureteral submucosal tunneling reimplantation combined with psoas hitch. The mean defective length was 5.5 cm (range 4-8 cm). The etiologies included ureteral strictures secondary to endoscopic laser lithotripsy in 2 patients, previous gynecological surgeries in 4, infiltrative ureteral endometriosis in 3, as well as ureteral strictures without obvious causes in the remaining 4. RESULTS: The operations were successfully performed in all patients. The mean operating time was 179 min (range 150-230 min). The mean estimated blood loss was 32 mL (range 15-80 mL). The mean drainage time was 5.8 days (range 4-8 days). No major complications occurred during the perioperative period. The mean follow-up time was 25 months. All patients experienced symptomatic relief and showed good urine drainage. CONCLUSION: Extravesical submucosal tunneling ureteroneocystostomy combined with psoas hitch under laparoscopy is a feasible and effective option for medium-length distal ureteral defects in selected patients.

Retroperitoneal infantile hemangioma: a case report and literature review.

BACKGROUND: Retroperitoneal infantile hemangioma (RIH), a type of primary retroperitoneal tumors, are exceptionally rare in clinical practice. Infantile hemangiomas typically manifest on the skin's surface. RIHs are exceptionally rare and typically small. In adults, these tumors often manifest without specific clinical symptoms or detectable signs for a definitive diagnosis. This case report details a patient diagnosed with RIH. We recommend complete excision of the tumor after a comprehensive evaluation, followed by postoperative pathology, to achieve a conclusive diagnosis. We believe that managing critical retroperitoneal structures and vessels intraoperatively presents a significant challenge for all procedures involving primary retroperitoneal tumors. A 47-year-old male was diagnosed with gallstones and underwent surgery 3 months ago at other institution for unexplained nausea and vomiting. Follow-up imaging 2 months after surgery revealed a retroperitoneal mass below the left renal pole. Upon presentation to our hospital, the patient continued to experience intermittent nausea and vomiting, with no other significant symptoms or signs. Considering the patient's 8-year history of hypertension, a paraganglioma was initially suspected. We performed the laparoscopic mass resection after a detailed assessment. However, postoperative pathology revealed it a capillary hemangioma (old term)/infantile hemangioma. CONCLUSION: RIHs are exceedingly rare benign tumor. The possibility of malignancy should be ruled out, and surgical resection is recommended following a thorough evaluation, with the diagnosis confirmed through pathological examination.

[Protective effect of haliotidis on the oxidative damage in the human lens epithelial cells].

OBJECTIVE: To study the influence of haliotidis extractive on the oxidative damage in the human lens epithelial cells cultured in vitro. METHODS: Experimental study. Cultured human lens epithelial cells in vitro were intervened with hydrogen peroxide caused oxidative damage model, at the same time added different concentrations of concha haliotidis extractive. With control experiment research cells were divided into the blank control group, positive control group hydrogen peroxide group and hydrogen peroxide and different concentrations of concha haliotidis group, and on the first, third, fifth day the activity of Cultured human lens epithelial cells were detected with Cell Counting Kit-8 (CCK-8) , cellular proliferation and morphological changes were observed with interred phase contrast microscope, and then on the third day chemical colorimetric were used to detect the homogenates superoxide dismutase(SOD), glutathione(GSH) and malondialdehyde (MDA) level. RESULTS: (1) At different time points there were variations between the activity of HLEC in each experimental group, Among each experimental group HLEC OD value of the cell vitality at 1 d, 3 d, 5 d , respectively were blank control group: 0.88, 1.28, 1.32; Positive control group: 0.73, 1.02, 1.06; 0.001% concha haliotis extract group: 0.73, 1.03, 1.06; 0.01% concha haliotis extract group: 0.76, 1.10, 1.13; 0.1% concha haliotis extract group: 0.79, 1.22, 1.21; 0.3% concha haliotis extract group: 0.79, 1.21, 1.21; the difference between groups was statistically significant (P < 0.05) (1 d, F = 23 922.42, P < 0.05;3 d, F = 120 605.86, P < 0.05; 5 d, F = 150 939.45, P < 0.05). H2O2 made the vitality of the cells reduce, concha haliotidis enhance its vitality, and in a certain range of time and concentrations there was dependence, with which the third day and 0.1% was the best. (2) After adding H2O2, the SOD and GSH level of HLEC reduced,(SOD 158.05 U/mgprot,GSH 15.05 mg/gprot) but MDA increased to 18.11 nmol/mgprot, concha haliotidis groups made the increase of antioxidant level(SOD 188.64 U/mgprot,GSH 21.05 mg/1000 mgprot)and the decrease of lipid peroxidation in oxidative damaged HLECs(MDA 14.16 nmol/mgprot), change had a statistical significance(P < 0.05) (SOD: F = 983.04, P < 0.05; GSH: F = 444.44, P < 0.05; MDA: F = 830.52, P < 0.05). (3)The chromatin of the positive control group concentrated and aggregated obviously, the aggregation of chromatin in concha haliotidis group lightened. CONCLUSION: The concha haliotidis can protect the cultured human lens epithelial cells in vitro which are oxidative injured, increased intracellular antioxidant levels, reduce the generation of hazardous products.

Energy Conversion and Transfer in the Luminescence of CeSc3(BO3)4:Cr3+ Phosphor.

Novel near-infrared (NIR) phosphors are in demand for light-emitting diode (LED) devices to extend their suitability for new applications and, in turn, support the sustainable and healthy development of the LED industry. The Cr3+ has been used as an activator in the development of new NIR phosphors. However, one main obstacle for the Cr3+-activated phosphors is the low luminescence efficiency due to the spin-forbidden d-d transition of Cr3+. The rare-earth (RE) huntite minerals that crystallize in the form of REM3(BO3)4 (M = Al, Sc, Cr, Fe, Ga) have a large family of members, including the rare-earth scandium borates of RESc3(BO3)4. Interestingly, in our research, we found that the luminescence efficiency of Cr3+ in the CeSc3(BO3)4 host, whose quantum yield was measured at 56%, is several times higher than that in GdSc3(BO3)4, TbSc3(BO3)4, and LuSc3(BO3)4 hosts. Hereby, the energy conversion and transfer in the luminescence of CeSc3(BO3)4:Cr3+ phosphor were examined. The Stokes shift of electron energy conversion within the Cr3+ 4T2g level for the emission at 818 nm and excitation at 625 nm in CeSc3(BO3)4 host was evaluated to be 3775.1 cm-1, and the super-large splitting energy of the 2F5/2 and 2F72 sub-states of the Ce3+ 4f1 state, about 3000 cm-1, was found in CeSc3(BO3)4 host. The typical electronic thermal vibration peaks were observed in the excitation spectra of CeSc3(BO3)4:Cr3+. On this basis, the smallest phonon energy, around 347.7 cm-1, of the CeSc3(BO3)4 host was estimated. Finally, the energy transfer that is responsible for the far higher photoluminescence of Cr3+ in CeSc3(BO3)4 than in other hosts was proven through the way of Ce3+ emission and Cr3+ reabsorption.

A systematic review and meta-analysis of the safety and efficacy of anti-thymocyte globulin combined with eltrombopag in the treatment of severe aplastic anemia.

BACKGROUND: When it comes to the treatment of aplastic anemia fever, the Guidelines for Aplastic Anemia regards Anti-thymocyte globulin (ATG) combined with eltrombopag as the standard immunosuppressive treatment plan, and ATG is the main mode to treat severe aplastic anemia. A large number of prospective studies and clinical trials have confirmed the clinical application value of eltrombopag in aplastic anemia. Although ATG combined with eltrombopag brings satisfactory treatment results, the safety of long-term use is still unclear. Therefore, more clinical trial studies are needed to verify its safety. METHODS: Literature in the Chinese and English medical databases was searched using the following search terms: "Antithymocyte globulin", "severed aplastic anemia" and "eltrombopag". Patients in the experimental group were administered ATG combined with eltrombopag and patients in the control group received ATG treatment alone. Rev Man5.3 software was used for meta-analysis. RESULTS: A total of 16 references were included in this meta-analysis. Heterogeneity tests examining total effective rate demonstrated that Chi2 =4.48, df =15, I2=0%<50%, and P=1.00>0.01. The effective rate of the experimental group was higher than that of the control group, with odds ratio (OR) =1.90 and 95% confidence interval (CI) 1.35 to 2.68 (Z=3.70, P=0.0002). The heterogeneity test results of the survival rate within 2 years were Chi2 =3.09, df =7, I2=0%<50%, and P=0.88>0.01. The survival rate of the experimental group was higher than that of the control group, with OR =2.54, and 95% CI: 1.58 to 4.09 (Z=3.84, P=0.0001). The heterogeneity test results of the mortality rate were Chi2 =3.49, df =6, I2=0%<50%, and P=0.75>0.01. The mortality rate of the experimental group was lower than that of the control group, with OR =0.48 and 95% CI: 0.33 to 0.70 (Z=3.84, P=0.0001). The heterogeneity test results of the occurrence of side effects were Chi2 =0.12, df =3, I2=0%<50%, P=0.99>0.01. The incidence of side effects in the experimental group was lower than that in the control group, with OR =0.74, 95% CI: 0.48 to 1.17 (Z=1.29, P=0.20). DISCUSSION: This meta-analysis demonstrated that the combination of ATG with eltrombopag in the treatment of SAA is safer and more effective than ATG alone.

Upregulation of microRNA-191 can serve as an independent prognostic marker for poor survival in prostate cancer.

MicroRNA-191 (miR-191) has been identified as being upregulated in several types of cancers, and plays the role of oncogene. The expression of miR-191 has been found to be upregulated in prostate cancer tissues as well as cell lines. In this study, we analyzed the correlation of miR-191 expression with clinicopathologic factors and prognosis in prostate cancer.Prostate cancer tissue samples and adjacent normal prostate tissue samples were collected from 146 patients who underwent laparoscopic radical prostatectomy between April 2013 and March 2018. Student two-tailed t-test was used for comparisons of 2 independent groups. The relationships between miR-191 expression and different clinicopathological characteristics were evaluated using the Chi-squared test. Kaplan-Meier survival plots and log-rank tests were used to assess the differences in overall survival of the different subgroups of prostate cancer patients.miR-191 expression was significantly higher in prostate cancer tissues compared with normal adjacent prostate tissues (P < .001). miR-191 expression was observed to be significantly correlated with Gleason score (P < .001), pelvic lymph node metastasis (P = .006), bone metastases (P < .001), and T stage (P = .005). Kaplan-Meier analysis showed that patients with higher levels of miR-191 had significantly poorer survival than those with lower expression of this miRNA in prostate cancer patients (log rank test, P = .011). Multivariate analysis revealed that miR-191 expression (hazard ratio [HR] = 2.311, 95% confidence interval, [CI]: 1.666-9.006; P = .027) was independently associated with the overall survival of prostate cancer patients.Our results demonstrated that miR-191 might serve as an independent prognostic indicator for prostate cancer patients.

The role of circulating miR-146a in patients with rheumatoid arthritis treated by Tripterygium wilfordii Hook F.

Rheumatoid arthritis (RA) is polygenic autoimmune disease with unclear etiology. MicroRNAs (miRNAs) play a critical role in the pathogenesis of RA. The objective of this study was to evaluate the role of miR-146a in patients with RA receiving Tripterygium wilfordii Hook F (TwHF) treatment.In total, 69 patients with RA and 69 healthy controls (HC) were included in the study, and patients with RA received TwHF treatment for 24 weeks. Blood samples were collected from RA patients and HC, and peripheral blood mononuclear cells (PBMCs) were isolated. Expression of miR-146a was analyzed in RA patients (baseline, 12 weeks and 24 weeks) and HC.Circulating miR-146a expression was markedly increased in patients with RA compared with healthy controls (P < .001), ROC analysis of miR-146a for diagnosis for RA showed that the AUC was 0.908 (95% CI: 0.862-0.955) with a sensitivity of 87.0% and a specificity of 82.6% at best cutoff. And miR-146a expression was positively associated with the DAS28 score and CRP level (P = .002 and P = .019). Moreover, miR-146a expression was markedly reduced after TwHF therapy (P < .001), and baseline miR-146a level was observed to present an increased tendency in responders compared with non-responders at 24 weeks (P = .066).Our study presented that circulating miR-146a level was correlated with risk and disease activity of RA patients by TwHF treatment, which could strikingly decrease expression of miR-146a in RA patients, and miR-146a may have a value in predicting clinical response of TwHF treatment. It indicates that circulating miR-146a plays a prominent role in RA patients treated by TwHF.